sentibio.com (SNTI): יחס חוב לטווח ארוך להון

Senti Biosciences, Inc. (SNTI) leverages the U.S. scientific foundation for creating programmable gene circuits designed for the targeted destruction of tumors. This long-term debt-to-equity ratio chart confirms financial stability, where the 0.00 mark indicates the level of credit leverage. Proprietary technology reduces the risk of side effects, and the implementation of "smart" products will serve as a long-term growth driver, with operating expenses already priced in by the market.

Senti Biosciences, Inc. (SNTI) invests in AI-driven gene therapy design, which requires significant capital for clinical trials. This ratio compares liabilities with a maturity of more than one year to equity, measuring the degree of financial leverage. By analyzing the current long-term debt-to-equity ratio on GURU.Markets, an investor assesses the company's reliance on borrowed funds. Reducing this leverage optimizes the cost of capital. A stable metric confirms the resilience of the business's market valuation.